Colleen Silk on Novo Nordisk Performance at ASH25
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”I’m so proud to have attended the 2025 ASH Annual Meeting in Orlando over the weekend alongside so many talented colleagues from our Hemoglobinopathies and Rare Blood Disorders teams.
It was so inspiring to see the dedication, expertise, and collaboration that went into making this meeting such a success for Novo Nordisk.
In addition to the great work that went into our exhibit booth and many poster and oral presentations, ASH was an invaluable opportunity to engage directly with the hematology community.
We had meaningful conversations with KOLs where we shared the science and our vision for expanding treatment options for people living with rare blood disorders and sickle cell disease.
These dialogues will help shape our path forward and accelerate the impact of our future portfolio.
A huge thank you to everyone who worked so hard to bring this to life.
From our US Field and Home Office cross-functional teams and our partners in Global, everyone contributed to making the congress truly outstanding.
I’m excited for what lies ahead for the Rare Disease team at Novo Nordisk as we continue to educate with the goal of bringing innovative therapies to patients who need them most.”
Stay updated with Hemostasis Today.
-
Dec 17, 2025, 15:24Laura Dormer on a Motor Relearning Program for Chronic Stroke Patients
-
Dec 17, 2025, 15:01WSO: United Nations Has Formally Adopted the Political Declaration on NCDs and Mental Health
-
Dec 17, 2025, 14:44Bryan Unger: 1st Patient Has Been Enrolled in NuvOx Therapeutics’ Phase IIb NOVEL Trial
-
Dec 17, 2025, 14:29Sarah Richardson: Feeling So Proud to Be a Part of the Advocacy Team for the HFA
-
Dec 17, 2025, 06:28Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
-
Dec 17, 2025, 06:11Lisa Murphy Thanks Stroke Foundation Team for An Impactful, Rewarding and Incredible Year
-
Dec 17, 2025, 06:05Emmanuel J Favaloro Shares A Study on AI and Machine Learning in Thrombosis and Hemostasis
-
Dec 17, 2025, 05:54Michael Bruckman: Fantastic to See Platelet-Inspired Nanoparticles Gaining Attention!
-
Dec 17, 2025, 04:00Peter Verhamme on Genetic Predisposition to Thromboembolism and COVID